{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:52Z","timestamp":1781927572546,"version":"3.54.5"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1248\/bpb.b25-00768","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:11:16Z","timestamp":1781907076000},"page":"983-988","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis"],"prefix":"10.1248","volume":"49","author":[{"given":"Kohei","family":"Kitagawa","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Okayama Psychiatric Medical Center, 3\u201316 Shikatahonmachi, Kita-ku, Okayama 700\u20130915, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Shujitsu University, 1\u20136\u20131 Nishigawara, Naka-ku, Okayama 703\u20138516, Japan"},{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Shujitsu University, 1\u20136\u20131 Nishigawara, Naka-ku, Okayama 703\u20138516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770\u20138503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770\u20138503, Japan"},{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima 770\u20130042, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nat. Rev. Neurol.<\/i>, <b>10<\/b>, 204\u2013216 (2014).","DOI":"10.1038\/nrneurol.2014.24"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Andhale R, Shrivastava D. Huntington\u2019s disease: a clinical review. <i>Cureus<\/i>, <b>14<\/b>, e28484 (2022).","DOI":"10.7759\/cureus.28484"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. <i>Neurology<\/i>, <b>66<\/b>, 366\u2013372 (2006).","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Bashir H, Jankovic J. Deutetrabenazine for the treatment of Huntington\u2019s chorea. <i>Expert Rev. Neurother.<\/i>, <b>18<\/b>, 625\u2013631 (2018).","DOI":"10.1080\/14737175.2018.1500178"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Schneider F, Stamler D, Bradbury M, Loupe PS, Hellriegel E, Cox DS, Savola JM, Gordon MF, Rabinovich-Guilatt L. Pharmacokinetics of deutetrabenazine and tetrabenazine: dose proportionality and food effect. <i>Clin. Pharmacol. Drug Dev.<\/i>, <b>10<\/b>, 647\u2013659 (2021).","DOI":"10.1002\/cpdd.882"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Frank S, Stamler D, Kayson E, <i>et al<\/i>. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. <i>JAMA Neurol.<\/i>, <b>74<\/b>, 977\u2013982 (2017).","DOI":"10.1001\/jamaneurol.2017.1352"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Atzrodt J, Derdau V, Kerr WJ, Reid M. Deuterium- and tritium-labelled compounds: applications in the life sciences. <i>Angew. Chem. Int. Ed.<\/i>, <b>57<\/b>, 1758\u20131784 (2018).","DOI":"10.1002\/anie.201704146"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Schmidt C. First deuterated drug approved. <i>Nat. Biotechnol.<\/i>, <b>35<\/b>, 493\u2013494 (2017).","DOI":"10.1038\/nbt0617-493"},{"key":"9","unstructured":"9) Frank S, Testa C, Edmondson MC, <i>et al<\/i>. The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study. <i>CNS Drugs<\/i>, <b>36<\/b>, 1207\u20131216 (2022)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Frank S, Testa CM, Stamler D, <i>et al<\/i>. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. <i>JAMA<\/i>, <b>316<\/b>, 40\u201350 (2016).","DOI":"10.1001\/jama.2016.8011"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kubota K. Signal detection from spontaneous reports: new methods in MCA in the UK, FDA in the U.S. and WHO. <i>Jpn. J. Pharmacoepidemiol.<\/i>, <b>6<\/b>, 101\u2013108 (2001).","DOI":"10.3820\/jjpe1996.6.101"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>54<\/b>, 315\u2013321 (1998).","DOI":"10.1007\/s002280050466"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ramdani Y, Largeau B, Jonville-Bera AP, Maillot F, Audemard-Verger A. COVID-19 vaccination as a trigger of IgA vasculitis: a global pharmacovigilance study. <i>J. Rheumatol.<\/i>, <b>50<\/b>, 564\u2013567 (2023).","DOI":"10.3899\/jrheum.220629"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Xia S, Gong H, Wang YK, Liu L, Zhao YC, Guo L, Zhang BK, Sarangdhar M, Noguchi Y, Yan M. <i>Pneumocystis jirovecii<\/i> pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the FAERS database. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1129730 (2023).","DOI":"10.3389\/fphar.2023.1129730"},{"key":"15","unstructured":"15) Yero T, Rey JA. Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease-related chorea. <i>P&amp;T<\/i>, <b>33<\/b>, 690\u2013694 (2008)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group\/TETRA-HD Investigators. <i>BMC Neurol.<\/i>, <b>9<\/b>, 62 (2009).","DOI":"10.1186\/1471-2377-9-62"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology<\/i>, <b>79<\/b>, 597\u2013603 (2012).","DOI":"10.1212\/WNL.0b013e318263c443"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. <i>J. Clin. Mov. Disord.<\/i>, <b>4<\/b>, 3 (2017).","DOI":"10.1186\/s40734-017-0051-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gupta H, Perkins W, Stark C, Kikkeri S, Kakazu J, Kaye AD. Deutetrabenazine for the treatment of chorea associated with Huntington\u2019s disease. <i>Health Psychol. Res.<\/i>, <b>10<\/b>, 36040 (2022).","DOI":"10.52965\/001c.36040"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Martorana A, Mori F, Esposito Z, Kusayanagi H, Monteleone F, Codec\u00e0 C, Sancesario G, Bernardi G, Koch G. Dopamine modulates cholinergic cortical excitability in Alzheimer\u2019s disease patients. <i>Neuropsychopharmacology<\/i>, <b>34<\/b>, 2323\u20132328 (2009).","DOI":"10.1038\/npp.2009.60"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Perlmutter JS, Tempel LW, Black KJ, Parkinson D, Todd RD. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. <i>Neurology<\/i>, <b>49<\/b>, 1432\u20131438 (1997).","DOI":"10.1212\/WNL.49.5.1432"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Falup-Pecurariu C, Diaconu \u0218, \u021a\u00een\u021b D, Falup-Pecurariu O. Neurobiology of sleep. <i>Exp. Ther. Med.<\/i>, <b>21<\/b>, 272 (2021).","DOI":"10.3892\/etm.2021.9703"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Schneider F, Bradbury M, Baillie TA, Stamler D, Hellriegel E, Cox DS, Loupe PS, Savola JM, Rabinovich-Guilatt L. Pharmacokinetic and metabolic profile of deutetrabenazine (TEV-50717) compared with tetrabenazine in healthy volunteers. <i>Clin. Transl. Sci.<\/i>, <b>13<\/b>, 707\u2013717 (2020).","DOI":"10.1111\/cts.12754"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yao Z, Wei X, Wu X, Katz JL, Kopajtic T, Greig NH, Sun H. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. <i>Eur. J. Med. Chem.<\/i>, <b>46<\/b>, 1841\u20131848 (2011).","DOI":"10.1016\/j.ejmech.2011.02.046"},{"key":"25","unstructured":"25) University Hospitals Cleveland Medical Center. \u201cDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\/Developmental Disabilities (TD-AIDD).\u201d: &lt;https:\/\/clinicaltrials.gov\/study\/NCT06997198&gt;, accessed 9 March, 2026."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b25-00768\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:39:24Z","timestamp":1781926764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b25-00768\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00768","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"article-number":"b25-00768"}}